Document text
Principal Investigator: Florian Krammer
Organization: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Fiscal Year: 2020
Award: $1,396,346
Funding agency: National Cancer Institute
PROJECT 1: ABSTRACT
Current information indicates that, in persons without cancer, natural infection with SARS-CoV-2 as well as
vaccination with COVID-19 vaccine candidates induce antibody responses to the spike protein of the virus
which should be protective against future infection. Lung cancer patients who become infected with SARS-
CoV-2 appear to develop severe COVID-19 with a high (35-40%) mortality rate indicating we urgently need to
plan for vaccine trials in this vulnerable population. Currently we have major knowledge gaps to fill in
preparation for such vaccine studies. These include: is there a higher incidence of SARS-CoV-2 in lung cancer
patients compared to the general population? Do lung cancer patients mount a comparable antibody response
in terms of quantity, quality, and longevity to people without lung cancer? Equally important are information in
lung cancer patients on the role of age, gender, smoking status, histology, and types of treatment for lung
cancer on both SARS-CoV-2 infection rate and generation of antibody responses. Through prospective
analyses of lung cancer cases (N= 1,000) and matched controls (N = 1,000) this Project “Characterization of
the Antibody Response to SARS-CoV-2 in Lung Cancer Patients” will provide answers to these important
questions through study of 4 specific aims and the use of our U54 Administrative, Clinical, and Data
Sciences Cores. Aim 1: Characterize the incident, magnitude and functionality of the antibody response to
SARS-CoV-2 in lung cancer patients versus non-lung cancer controls. Aim 2: Compare the longevity of the
antibody response against SARS-CoV-2 in lung cancer patients versus non-lung cancer controls. Aim 3:
Evaluate the impact of patient demographics and cancer-associated clinical factors on the antibody response
in lung cancer patients. And Aim 4: Characterize antibody responses to SARS-CoV-2 vaccination in lung
cancer patients versus non-lung cancer controls. The patient serology specimens will also be studied for viral
neutralizing functionality in collaboration with U54 Project 2. We have assembled a world-class team of lung
cancer clinical translational investigators, serology and virology experts, and patient advocates to address
these key issues. The results of this Project will have a significant impact on lung cancer patient management
during the COVID-19 pandemic, and even greater impact on designing optimal SARS-CoV-2 vaccination
regimens for lung cancer patients.
Terms: <2019 novel coronavirus><2019-nCoV><Address><Advocate><Age><Antibodies><Antibody Response><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Binding><Bioassay><Biologic Assays><Biological Assay><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID-19 vaccine><COVID19><COVID19 epidemic><COVID19 pandemic><COVID19 vaccine><Cancer Control><Cancer Control Science><Cancer Patient><Cancer Treatment><Cancers><Cell Body><Cells><Clinical><Clinical Sciences><Clinical Trials><Collaborations><Complement><Complement Proteins><Coronaviridae><Coronavirus><Cricetinae><Data Science Core><Data Science Resource Core><Demographic Impact><Development><Epithelial Cells><Ethnic Origin><Ethnicity><Fc Receptor><Future><Gender><General Population><General Public><Generations><Glycoproteins><Hamsters><Hamsters Mammals><Histology><Immune><Immune response><Immunes><Immunity><Immunological response><Incidence><Individual><Infection><Kinetics><Knowledge><Length of Life><Longevity><Lung><Lung Respiratory System><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Mediating><Modeling><Molecular Interaction><Patients><Persons><Policies><Population><Predisposition><Preparation><Pulmonary Cancer><Pulmonary malignant Neoplasm><Race><Racial Group><Racial Stocks><Receptor Protein><Regimen><Research Specimen><Role><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Serologic><Serologic tests><Serological><Serological Tests><Severe acute respiratory syndrome coronavirus 2><Smoking History><Smoking Status><Specimen><Statistical Data Analyses><Statistical Data Analysis><Statistical Data Interpretation><Susceptibility><Testing><Vaccinated><Vaccination><Vaccines><Viral><Viral Antigens><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virus><Vulnerable Populations><Work><Wuhan coronavirus><ages><anti-cancer therapy><anti-viral agents><anti-viral drugs><anti-virals><antibody receptor><anticancer therapy><base><cancer cell><cancer therapy><case control><co-morbid><co-morbidity><comorbidity><comparative><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><coronavirus disease 2019 vaccine><cytokine><demographics><design><designing><developmental><host response><immunoresponse><infection rate><insight><inter-individual variability><inter-individual variation><interindividual variation><life span><lifespan><lung cancer><malignancy><mortality><neoplasm/cancer><neutralizing antibody><patient response><patient specific response><power analysis><prospective><protective efficacy><pulmonary><rate of infection><receptor><response><responsive patient><serology><seropositive><social role><statistical analysis><trait><translational investigator><translational researcher><translational scientist><vaccination study><vaccination trial><vaccine candidate><vaccine response><vaccine study><vaccine trial><virology><virus antigen><virus protein><vulnerable group>